Drug Repurposing: Far Beyond New Targets for Old Drugs

被引:190
作者
Oprea, T. I. [1 ,2 ]
Mestres, J. [3 ,4 ]
机构
[1] 1 Univ New Mexico, Univ New Mexico Sch Med, Dept Internal Med, Translat Informat Div, Albuquerque, NM 87131 USA
[2] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] IMIM Hosp Mar Res Inst, Res Program Biomed Informat GRIB, Chemogen Lab, Barcelona 08003, Catalonia, Spain
[4] Univ Pompeu Fabra, Barcelona 08003, Catalonia, Spain
来源
AAPS JOURNAL | 2012年 / 14卷 / 04期
关键词
drug repurposing; drug-target interactions; intellectual property; side effect tolerance; target identification; CYCLOOXYGENASE-2; INHIBITOR; DISCOVERY; PHARMACOLOGY; CELECOXIB;
D O I
10.1208/s12248-012-9390-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug-target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.
引用
收藏
页码:759 / 763
页数:5
相关论文
共 40 条
[1]  
[Anonymous], 2004, SCIENCE, V303, P1798, DOI 10.1126/science.303.5665.1796
[2]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[3]   Cross-Pharmacology Analysis of G Protein-Coupled Receptors [J].
Brianso, Ferran ;
Carrascosa, Maria C. ;
Oprea, Tudor I. ;
Mestres, Jordi .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (15) :1956-1963
[4]   Drug target identification using side-effect similarity [J].
Campillos, Monica ;
Kuhn, Michael ;
Gavin, Anne-Claude ;
Jensen, Lars Juhl ;
Bork, Peer .
SCIENCE, 2008, 321 (5886) :263-266
[5]   A chemogenomic approach to drug discovery: focus on cardiovascular diseases [J].
Cases, Montserrat ;
Mestres, Jordi .
DRUG DISCOVERY TODAY, 2009, 14 (9-10) :479-485
[6]   New uses for old drugs [J].
Chong, Curtis R. ;
Sullivan, David J., Jr. .
NATURE, 2007, 448 (7154) :645-646
[7]   Mining for therapeutic gold [J].
Collins, Francis S. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :397-397
[8]   Drug discovery in jeopardy [J].
Cuatrecasas, Pedro .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (11) :2837-2842
[9]  
Curley D, 2009, BIOSCIENCE LAW REV, V10, P131
[10]   The molecular basis for coxib inhibition of p38α MAP kinase [J].
da Silva, GMS ;
Lima, LM ;
Fraga, CAM ;
Sant'Anna, CMR ;
Barreiro, EJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (15) :3506-3509